Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.

Andrew M Blumenfeld,Ramesh Boinpally,Rosa De Abreu Ferreira,Joel M Trugman,Brett Dabruzzo,Jessica Ailani,Richard B Lipton

Headache（2023）

引用 2|浏览15

暂无评分

摘要

The combination use of atogepant and ubrogepant was safe and well tolerated in adult participants with a history of migraine enrolled in the study. Pharmacokinetic changes during co-administration were not clinically meaningful.

查看译文

关键词

CGRP receptor antagonists,atogepant,drug-drug interaction,migraine,ubrogepant

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要